Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Gene Therapies for Cancer: Strategies, Challenges and Successes
2014
Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer
2008
Molecular mechanisms mediating metastasis of hypoxic breast cancer cells
2012 StandoutNobel
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial
2008
Triple-Negative Breast Cancer: An Unmet Medical Need
2011
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
Obesity and Kidney Disease: Hidden Consequences of the Epidemic
2017 Standout
Prevention of febrile neutropenia: use of prophylactic antibiotics
2009
Microsatellite Instability in Colorectal Cancer
2010 Standout
Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
2014 Standout
XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy
2009
Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1
2010 Standout
Enhanced delivery of mda-7/IL-24 using a serotype chimeric adenovirus (Ad.5/3) improves therapeutic efficacy in low CAR prostate cancer cells
2010
XM02 is superior to placebo and equivalent to Neupogen™ in reducing the duration of severe neutropenia and the incidence of febrile neutropenia in cycle 1 in breast cancer patients receiving docetaxel/doxorubicin chemotherapy
2008
Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: A randomized phase 2 trial
2007
Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: Results from an integrated analysis
2008
Development of a new G-CSF product based on biosimilarity assessment
2009
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
2008
Role of Gemcitabine in Breast Cancer Management: An Update
2006
Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice
2020 Standout
Effect of pegylation on pharmaceuticals
2003 Standout
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Clinical uses of pegylated pharmaceuticals in oncology
2002
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
2021 StandoutNobel
Hematopoietic growth factors: ESMO Recommendations for the applications
2009
Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain - results of the LEARN Study
2008
An Update on the Current and Emerging Targeted Agents in Metastatic Colorectal Cancer
2011
PTEN loss in the continuum of common cancers, rare syndromes and mouse models
2011
IL‐24: a classic cytokine and/or a potential cure for cancer?
2008
The role of the IL-22/IL-22R1 axis in cancer
2014
Kinematic and Clinical Analyses of Upper-Extremity Movements After Constraint-Induced Movement Therapy in Patients With Stroke: A Randomized Controlled Trial
2007
Chemotherapy dose intensity in non-Hodgkin's lymphoma: is dose intensity an emerging paradigm for better outcomes?
2005
Polymer conjugates as anticancer nanomedicines
2006 Standout
Akt inhibitors in clinical development for the treatment of cancer
2010
Canadian Supportive Care Recommendations for the Management of Neutropenia in Patients with Cancer
2008
Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma
2007
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
MDA‐7/IL‐24 regulates proliferation, invasion and tumor cell radiosensitivity: A new cancer therapy?
2005
Pegfilgrastim: A New Therapy to Prevent Neutropenic Fever
2002
Once-per-cycle pegfilgrastim (Neulasta) for the management of chemotherapy-induced neutropenia
2003
EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours
2006
Open-label, Randomized Study of Pegfilgrastim vs. Daily Filgrastim as an Adjunct to Chemotherapy in Elderly Patients with Non-Hodgkin's Lymphoma
2003
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
2007
Designing hydrogels for controlled drug delivery
2016 Standout
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
2012 Standout
Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices
2007
Risk of Febrile Neutropenia among Patients with Intermediate-grade non-Hodgkin's Lymphoma Receiving CHOP Chemotherapy
2003
Cisplatin: The first metal based anticancer drug
2019 Standout
Structure and function of interleukin-22 and other members of the interleukin-10 family
2010
Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities
2008 Standout
Clonal evolution in cancer
2012 StandoutNature
The colony-stimulating factors and cancer
2010
The functions and regulation of the PTEN tumour suppressor
2012 Standout
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
Neutrophils in cancer: neutral no more
2016 Standout
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Hematopoietic growth factors: ESMO Clinical Practice Guidelines for the applications
2010
XM02, the First Biosimilar G-CSF, is Safe and Effective in Reducing the Duration of Severe Neutropenia and Incidence of Febrile Neutropenia in Patients with Small Cell or Non-small Cell Lung Cancer Receiving Platinum-Based Chemotherapy
2009
Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers
2016 Standout
Quality of Life and Chemotherapy-induced Neutropenia
2005
Effective drug delivery by PEGylated drug conjugates
2003
Motor recovery after stroke: a systematic review
2009 Standout
Serum Pegfilgrastim Concentrations During Recovery of Absolute Neutrophil Count in Patients with Cancer Receiving Pegfilgrastim After Chemotherapy
2007
Triple-negative breast cancer—current status and future directions
2009
Chemotherapy‐induced neutropenia
2004
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Pharmacokinetic Consequences of Pegylation
2006
The dawning era of polymer therapeutics
2003 Standout
The cancer genome
2009 StandoutNature
Molecular Testing in Colorectal Cancer
2012
Clearance Properties of Nano-Sized Particles and Molecules as Imaging Agents: Considerations and Caveats
2008 Standout
Trastuzumab in the management of early and advanced stage breast cancer.
2007
ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context
2012 Standout
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America
2011 Standout
Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group
2004
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Nanotechnology for Multimodal Synergistic Cancer Therapy
2017 Standout
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
Cost-Effectiveness of Adding Granulocyte Colony-Stimulating Factor to Primary Prophylaxis With Antibiotics in Small-Cell Lung Cancer
2006
Risk Models for Predicting Chemotherapy-Induced Neutropenia
2005
Impact of Five Prophylactic Filgrastim Schedules on Hematologic Toxicity in Early Breast Cancer Patients Treated With Epirubicin and Cyclophosphamide
2005
First and Subsequent Cycle Use of Pegfilgrastim Prevents Febrile Neutropenia in Patients With Breast Cancer: A Multicenter, Double-Blind, Placebo-Controlled Phase III Study
2005
FDA-approved poly(ethylene glycol)–protein conjugate drugs
2011
Randomized, Multicenter, Open-Label Study of Pegfilgrastim Compared With Daily Filgrastim After Chemotherapy for Lymphoma
2003
Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
2006
Phase III Trial of Paclitaxel at Two Dose Levels, the Higher Dose Accompanied by Filgrastim at Two Dose Levels in Platinum-Pretreated Epithelial Ovarian Cancer: An Intergroup Study
2003
Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice
2005
Systematic review of the clinical effectiveness and cost-effectiveness of capecitabine (Xeloda®) for locally advanced and/or metastatic breast cancer
2004
Withaferin-A suppress AKT induced tumor growth in colorectal cancer cells
2016
Regulation and Functions of the IL-10 Family of Cytokines in Inflammation and Disease
2011 Standout
Metal–Organic Framework (MOF)‐Based Drug/Cargo Delivery and Cancer Therapy
2017 Standout
Minimizing Cardiotoxicity While Optimizing Treatment Efficacy with Trastuzumab: Review and Expert Recommendations
2009
Works of S. Vukelja being referenced
Xeloda (capecitabine) plus docetaxel combination therapy in locally advanced/metastatic breast cancer: Latest results
2001
Clinical and local biological effects of an intratumoral injection of mda-7 (IL24; INGN 241) in patients with advanced carcinoma: a phase I study
2004
Phase II Study of Trastuzumab plus Gemcitabine in Chemotherapy-Pretreated Patients with Metastatic Breast Cancer
2004
Activity of oral irinotecan (IRI) in metastatic breast cancer (MBC) patients after prior anthracycline, taxane and capecitabine: Phase 2 study results
2005
Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer
2009
A randomized, multicenter phase III trial comparing doxorubicin + cyclophosphamide followed by paclitaxel or doxorubicin + paclitaxel followed by weekly paclitaxel as adjuvant therapy for high-risk breast cancer
2007
A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer.
2009
Blinded, Randomized, Multicenter Study to Evaluate Single Administration Pegfilgrastim Once per Cycle Versus Daily Filgrastim as an Adjunct to Chemotherapy in Patients With High-Risk Stage II or Stage III/IV Breast Cancer
2002
Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
2011
Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC).
2010